Tirzepatide showed a significant reduction in LFC and VAT and in ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study (55). The gene discussed is INS; the disease is type 2 diabetes mellitus.